Abarceo Pharma

Abarceo Pharma has identified a novel treatment of type-2 diabetes which addresses the disease at the root and allows patients to produce their insulin again, naturally.

Abarceo Pharma

CEO:

Kristian Hansen

First investment year:

2021

Business sector:

Life Science, Drug development

Investment manager: Helen Pettersson Visit website